Mersana Therapeutics, Inc. (MRSN) Reaches $19.88 After 5.00% Up Move; Capital Fund Management Sa Lifted By $11.73 Million Its Cummins (Call) (CMI) Position

June 17, 2018 - By Linda Rogers

Cummins Inc. (NYSE:CMI) Logo

The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a huge mover today! The stock increased 13.47% or $2.36 during the last trading session, reaching $19.88. About 218,264 shares traded or 67.34% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical MRSN News: ; 09/04/2018 – Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the Ame; 25/04/2018 – Mersana Therapeutics Closes Above 200-Day Average: Technicals; 17/05/2018 – Mersana Therapeutics Presenting at Conference Jun 4; 15/05/2018 – Ghost Tree Capital Buys 1.2% of Mersana Therapeutics Inc; 07/05/2018 – Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates; 28/03/2018 – Mersana Therapeutics Presenting at Conference Apr 14; 17/05/2018 – REG-INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer; 19/03/2018 – MERSANA THERAPEUTICS INC – INCREASED SIZE OF BOARD FROM 7 TO 8 DIRECTORS, APPOINTED WILLARD H. DERE TO SERVE AS CLASS l DIRECTOR; 12/03/2018 ADXS, $AZN.GB: $ADXS Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab) – ! $AZN.GB $ADXS; 22/05/2018 – Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual MeetiThe move comes after 9 months positive chart setup for the $455.29 million company. It was reported on Jun, 17 by Barchart.com. We have $20.87 PT which if reached, will make NASDAQ:MRSN worth $22.76 million more.

Capital Fund Management Sa increased Cummins Inc (Call) (CMI) stake by 2496.55% reported in 2018Q1 SEC filing. Capital Fund Management Sa acquired 72,400 shares as Cummins Inc (Call) (CMI)’s stock declined 14.62%. The Capital Fund Management Sa holds 75,300 shares with $12.21 million value, up from 2,900 last quarter. Cummins Inc (Call) now has $23.51 billion valuation. The stock increased 0.87% or $1.24 during the last trading session, reaching $143.13. About 1.73 million shares traded or 11.31% up from the average. Cummins Inc. (NYSE:CMI) has declined 5.98% since June 17, 2017 and is downtrending. It has underperformed by 18.55% the S&P500. Some Historical CMI News: ; 01/05/2018 – Cummins 1Q Adj EPS $2.43; 01/05/2018 – Cummins Had Seen 2018 Revenue Up 4%-8%; 24/05/2018 – CUMMINS INDIA LTD CUMM.NS – CO IS POSITIVE ON MEDIUM TO LONG TERM OUTLOOK FOR DOMESTIC SALES AS UNDERLYING DEMAND CONDITIONS REMAIN POSITIVE; 14/03/2018 – Allison Transmission Receives California Air Resources Bd Certification for 2018 Hybrid-Electric Propulsion System Paired With Cummins Engines; 14/03/2018 – Allison Transmission receives certification from California Air Resources Board for model year 2018 hybrid-electric propulsion system paired with Cummins engines; 13/04/2018 – Cummins Could Regain Its Highs — Barrons.com; 01/05/2018 – CUMMINS 1Q EPS $1.96; 24/05/2018 – BSE Mumbai Bourse: Results from KPIT Cummins Infosystems for Jan 01 to Mar 31; 17/04/2018 – MEDIA-GE’s Jenbacher is attracting interest from Cummins, CVC – Bloomberg; 24/05/2018 – CUMMINS INDIA 4Q TOTAL COSTS 10.9B RUPEES

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, July 24 by Cowen & Co. The rating was initiated by Leerink Swann on Monday, July 24 with “Buy”. J.P. Morgan initiated Mersana Therapeutics, Inc. (NASDAQ:MRSN) rating on Monday, July 24. J.P. Morgan has “Buy” rating and $2300 target.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $455.29 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: Globenewswire.com which released: “Investor Expectations to Drive Momentum within The Kroger, Mohawk Industries, Mersana Therapeutics, Riot …” on June 14, 2018, also Nasdaq.com with their article: “Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018” published on June 04, 2018, Nasdaq.com published: “Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical …” on May 22, 2018. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” published on May 25, 2018 as well as Benzinga.com‘s news article titled: “45 Biggest Movers From Yesterday” with publication date: June 06, 2018.

Analysts await Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report earnings on August, 10. They expect $-0.58 EPS, up 90.84% or $5.75 from last year’s $-6.33 per share. After $-0.54 actual EPS reported by Mersana Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.

Capital Fund Management Sa decreased Southern Copper Corp (Call) (NYSE:SCCO) stake by 240,500 shares to 25,800 valued at $1.40 million in 2018Q1. It also reduced Aetna Inc (Call) (NYSE:AET) stake by 3,900 shares and now owns 2,200 shares. Concho Resources Inc (Call) (NYSE:CXO) was reduced too.

Among 30 analysts covering Cummins (NYSE:CMI), 7 have Buy rating, 2 Sell and 21 Hold. Therefore 23% are positive. Cummins had 116 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was initiated by Seaport Global on Thursday, April 6 with “Neutral”. The stock has “Hold” rating by RBC Capital Markets on Monday, June 5. The rating was maintained by Oppenheimer on Wednesday, May 2 with “Outperform”. The stock of Cummins Inc. (NYSE:CMI) earned “Underperform” rating by Bank of America on Tuesday, December 1. The rating was downgraded by Deutsche Bank to “Hold” on Tuesday, September 22. Piper Jaffray maintained Cummins Inc. (NYSE:CMI) on Friday, December 8 with “Hold” rating. BMO Capital Markets downgraded it to “Market Perform” rating and $110 target in Tuesday, October 6 report. The firm has “Sell” rating given on Wednesday, October 12 by Deutsche Bank. The firm earned “Hold” rating on Wednesday, September 6 by Jefferies. The firm has “Hold” rating given on Wednesday, October 18 by Stifel Nicolaus.

Cummins Inc. (NYSE:CMI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>